Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab with Chemoradiation in Limited-Stage Small Cell Lung Cancer
NCT03585998Phase 2Unknown
- Sponsor
- Samsung Medical Center
- Start
- Jun 2018
- Primary completion
- Jun 2021
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab in small cell lung cancer (SCLC), sponsored by Samsung Medical Center. Status: unknown.
02
Drugs
durvalumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT03585998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03585998.